Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Part of paid clinical trials in Los Angeles, California.

Sponsor
Immunocore Ltd
Study ID
NCT03973333
Phase
PHASE1/PHASE2
Status
Withdrawn

Conditions

  • Select Advanced Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • IMC-C103C — DRUG
    Weekly IV infusions
  • Atezolizumab — DRUG
    IV infusions every 3 weeks
  • IMC-C103C — DRUG
    Weekly subcutaneous Injection

Study Details

IMC-C103C is an immune mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen MAGE-A4. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-C103C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for MAGE-A4.

Key Dates

Start date
May 17, 2019
Status verified
Oct 2024
Primary completion
Sep 25, 2023
Completion
Sep 25, 2023

Study Design

Enrollment
0 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: IMC-C103C - Monotherapy IV dose escalation
    n= approximately 50 patients to establish the MTD/expansion dose
  • Experimental: IMC-C103C and atezolizumab dose escalation
    n=approximately 12 patients to establish the MTD/expansion dose
  • Experimental: IMC-C103C - expansion
    Patients will be enrolled n=9-24 per expansion cohort (up to 4 total): metastatic/unresectable tumors of interest patients treated at the expansion dose of IMC-C103C to assess preliminary anti-tumor efficacy
  • Experimental: IMC-C103C monotherapy SC dose escalation
    Patients will be enrolled n=9-12 to establish the MTD/expansion dose

Primary Outcome Measure

Phase 1: Incidence of dose-limiting toxicities (DLT) [ Time Frame: From first dose to DLT period (28 days) ]

Locations (10)

FacilityCityStateZIPSite coordinators
The Angeles Clinic and Research InstituteLos AngelesCalifornia90025-
University of California Davis Comprehenvise Cancer CenterSacramentoCalifornia95817-
University of Colorado Cancer CenterAuroraColorado80045-
The University of Chicago Medicine & Biological SciencesChicagoIllinois60637-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
Oklahoma University Medical CenterOklahoma CityOklahoma73104-
Thomas Jefferson University HospitalPhiladelphiaPennsylvania19107-
UPMC Cancer CenterPittsburghPennsylvania15213-
Sarah Cannon Research Institute at Tennessee OncologyNashvilleTennessee37203-
MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Los Angeles, CA

By research site
The Angeles Clinic and Research Institute· Los Angeles, CAUniversity of California Davis Comprehenvise Cancer Center· Sacramento, CAUniversity of Colorado Cancer Center· Aurora, COThe University of Chicago Medicine & Biological Sciences· Chicago, ILMemorial Sloan Kettering Cancer Center· New York, NYOklahoma University Medical Center· Oklahoma City, OK

Related Studies